APRIL: spring forward also for IgA vasculitis nephritis in children.
The article discusses the use of telitacicept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), in treating refractory childhood IgA vasculitis nephritis (IgAVN). IgAVN is a common pediatric vasculitis that can lead to kidney involvement, and the artic...
| Publicado en: | Pediatric Nephrology Vol. 41; no. 1; pp. 1 - 10 |
|---|---|
| Autor principal: | |
| Formato: | commentary editorial pictorial tables/charts Journal Article |
| Publicado: |
Springer Nature
Jan2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| Sumario: | The article discusses the use of telitacicept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), in treating refractory childhood IgA vasculitis nephritis (IgAVN). IgAVN is a common pediatric vasculitis that can lead to kidney involvement, and the article highlights the challenges in treating this condition, particularly due to the lack of controlled studies. Recent real-world data indicate that telitacicept may significantly reduce proteinuria and improve kidney function in children with IgAVN, with minimal side effects reported. The findings suggest a potential shift in treatment strategies for IgAVN, emphasizing the need for further research to validate these results and explore the long-term effects of such therapies. |
|---|